A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)
Known End Stage Renal Disease (ESRD) or history of active nephrotic syndrome within the last 3 months.
Known Stage 2-3 AKI within last 2 weeks.
Terminally ill (defined as expectation of death within 6 months), has a do not resuscitate order that would restrict protocol-required procedures, or is being admitted only for palliative care.
History of solid organ transplant and receiving calcineurin inhibitors.
Documented serious allergy (i.e. anaphylaxis) to vancomycin, aminoglycosides, penicillins, or cephalosporins (intravenous or oral).
Known current serum total bilirubin \> 4mg/dL.
Subjects already included in an observational study can be co-enrolled in LAPIS. Subjects already included in an interventional study may be enrolled with pre-approval of the sponsor according to the following rules:
1. Co-enrollment in LAPIS will not be allowed with investigational drug and device studies;
2. Studies may be allowed if AKI or kidney function is not an endpoint with pre-approval of the LAPIS sponsor;
3. Co-enrollment in LAPIS will not be allowed if co-enrollment is an exclusion criterion in the other study.
Subjects with laboratory confirmed COVID-19 infection as the primary reason for hospital admission.